[go: up one dir, main page]

DE602004008227D1 - Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase - Google Patents

Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase

Info

Publication number
DE602004008227D1
DE602004008227D1 DE602004008227T DE602004008227T DE602004008227D1 DE 602004008227 D1 DE602004008227 D1 DE 602004008227D1 DE 602004008227 T DE602004008227 T DE 602004008227T DE 602004008227 T DE602004008227 T DE 602004008227T DE 602004008227 D1 DE602004008227 D1 DE 602004008227D1
Authority
DE
Germany
Prior art keywords
inhibitors
reverse transcriptase
nucleoside
nucleoside inhibitors
transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004008227T
Other languages
English (en)
Other versions
DE602004008227T2 (de
Inventor
James Patrick Dunn
Joan Heather Hogg
Taraneh Mirzadegan
Steven Swallow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004008227D1 publication Critical patent/DE602004008227D1/de
Application granted granted Critical
Publication of DE602004008227T2 publication Critical patent/DE602004008227T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004008227T 2003-02-18 2004-02-17 Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase Expired - Lifetime DE602004008227T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44797403P 2003-02-18 2003-02-18
US447974P 2003-02-18
PCT/EP2004/001477 WO2004074257A1 (en) 2003-02-18 2004-02-17 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
DE602004008227D1 true DE602004008227D1 (de) 2007-09-27
DE602004008227T2 DE602004008227T2 (de) 2008-05-15

Family

ID=32908518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008227T Expired - Lifetime DE602004008227T2 (de) 2003-02-18 2004-02-17 Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase

Country Status (17)

Country Link
US (1) US7241794B2 (de)
EP (1) EP1597235B1 (de)
JP (1) JP4608480B2 (de)
KR (1) KR100776093B1 (de)
CN (1) CN100389109C (de)
AR (1) AR043195A1 (de)
AT (1) ATE370124T1 (de)
BR (1) BRPI0407591A (de)
CA (1) CA2515151C (de)
CL (1) CL2004000270A1 (de)
DE (1) DE602004008227T2 (de)
ES (1) ES2291854T3 (de)
MX (1) MXPA05008748A (de)
PL (1) PL378556A1 (de)
RU (1) RU2305680C2 (de)
TW (1) TW200423930A (de)
WO (1) WO2004074257A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011922A (es) * 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CN101415691B (zh) 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
CN101415687B (zh) 2006-02-06 2012-02-08 大正制药株式会社 鞘氨醇-1-磷酸结合抑制物质
ATE544755T1 (de) * 2006-02-14 2012-02-15 Ihara Chemical Ind Co Verfahren zur herstellung einer 5-alkoxy-4- hydroxymethylpyrazolverbindung
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
WO2008019968A1 (en) * 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
BRPI0809617A2 (pt) * 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
HRP20120363T1 (hr) 2007-08-01 2012-05-31 Taisho Pharmaceutical Co. Inhibitor vezivanja s1p1
EP2225239B1 (de) * 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Heterozyklische antivirale verbindungen
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
ME02181B (me) * 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze
ES2565193T3 (es) 2010-07-15 2016-04-01 Sumitomo Dainippon Pharma Co., Ltd. Compuesto de pirazol
EP2508511A1 (de) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitoren der Virenreplikation, Verfahren zu deren Herstellung und deren therapeutische Verwendung
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
RU2015101532A (ru) 2012-06-20 2016-08-20 Вандербилт Юниверсити Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5
US9029366B2 (en) 2012-06-20 2015-05-12 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP6404230B2 (ja) 2012-12-20 2018-10-10 インセプション ２、 インコーポレイテッド トリアゾロン化合物およびその使用
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
LT3125894T (lt) 2014-04-01 2020-12-10 Merck Sharp & Dohme Corp. Živ atvirkštinės transkriptazės inhibitorių provaistai
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
BR112017018140A2 (pt) * 2015-03-19 2018-04-10 Du Pont ?composto, composição fungicida e método de controle de doenças de plantas?
US20200002283A1 (en) * 2016-06-29 2020-01-02 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain
CN110818636A (zh) * 2019-11-29 2020-02-21 河北科技大学 一种化合物或其盐及其应用和合成方法
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183931B1 (pl) 1994-09-26 2002-08-30 Shionogi & Co Nowe związki, pochodne imidazolu i kompozycje farmaceutyczne je zawierające
DE19734664A1 (de) * 1997-08-11 1999-02-18 Bayer Ag (Hetero)Aryloxypyrazole
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
GB0028484D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
BRPI0208811B8 (pt) * 2001-04-10 2021-05-25 Pfizer derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives

Also Published As

Publication number Publication date
AR043195A1 (es) 2005-07-20
US7241794B2 (en) 2007-07-10
CL2004000270A1 (es) 2005-02-04
WO2004074257A1 (en) 2004-09-02
KR100776093B1 (ko) 2007-11-15
RU2305680C2 (ru) 2007-09-10
TW200423930A (en) 2004-11-16
DE602004008227T2 (de) 2008-05-15
AU2004213134A1 (en) 2004-09-02
JP2006515339A (ja) 2006-05-25
PL378556A1 (pl) 2006-05-02
EP1597235A1 (de) 2005-11-23
MXPA05008748A (es) 2005-09-20
US20040192666A1 (en) 2004-09-30
KR20050105471A (ko) 2005-11-04
RU2005128832A (ru) 2006-04-27
ES2291854T3 (es) 2008-03-01
EP1597235B1 (de) 2007-08-15
BRPI0407591A (pt) 2006-02-14
CN100389109C (zh) 2008-05-21
CN1751028A (zh) 2006-03-22
CA2515151A1 (en) 2004-09-02
CA2515151C (en) 2010-11-30
ATE370124T1 (de) 2007-09-15
JP4608480B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
DE602004008227D1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
DE602005017604D1 (de) Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
ATE425138T1 (de) N-phenyl-phenylacetamid-nichtnukleosidinhibitor n reverser transkriptase
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
PL1636190T3 (pl) Trwały kryształ związku 4-oksochinoliny
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DE60324418D1 (de) Nicht-nukleosidische inhibitoren der reversen transkriptase
NO20054264D0 (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
EP1788874A4 (de) Salze von 5-azacytidin
ATE459624T1 (de) Inhibitoren der reversen transkriptase des hiv
ATE322492T1 (de) Nicht-nukleosid reverse transkriptase inhibitoren
BRPI0714509A2 (pt) Inibidores de transcriptase reversa de não-nucleosídeo.
IL157543A0 (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
EP1910272A4 (de) Renininhibitoren
DK1799707T3 (da) Rekombineret Kunitztypeinhibitor
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
EP1899340A4 (de) Nicht-nukleosidische reverse-transkriptase-hemmer
DE60326035D1 (de) Dipyridodiazepinone als inhibitoren der reversen transkriptase
DK1373267T3 (da) Non-nucleoside revers transkriptase-inhibitorer
FR2863148B1 (fr) Egrappoir separateur-trieur de la vendange
ES1054657Y (es) Elemento para la formacion de muebles

Legal Events

Date Code Title Description
8364 No opposition during term of opposition